The Lead Episode 142: A Discussion of Class 1c Antiarrhythmic Therapy Following PCI in New Onset Atrial Fibrillation: Safety and Clinical Outcomes from a Nationwide Cohort

The Lead Episode 142: A Discussion of Class 1c Antiarrhythmic Therapy Following PCI in New Onset Atrial Fibrillation: Safety and Clinical Outcomes from a Nationwide Cohort

April 2, 2026 · 24 min · Season 4 · Episode 142

About this episode

The episode discusses the safety and clinical outcomes of Class 1c antiarrhythmic therapy following PCI in patients with new-onset atrial fibrillation.

Join an expert-led discussion exploring the safety and clinical outcomes of Class 1c antiarrhythmic therapy following percutaneous coronary intervention (PCI) in patients with new-onset atrial fibrillation, based on insights from a nationwide cohort study. Deep Chandh Raja, MBBS, MD, PhD (Australian National University and Kauvery Hospital) hosts a dynamic conversation with Sandeep Gautam, MD, MPH, FHRS (University of Missouri Health) and Deepak Padmanabhan, MD, FHRS (Narayana Institute of Cardiac Sciences, Bengaluru). Together, they examine real-world data on the use of Class 1c agents in a traditionally high-risk population, addressing long-standing concerns about proarrhythmia and ischemic heart disease. The discussion will highlight patient selection, evolving clinical practice patterns, and implications for guideline-directed management, offering clinicians practical insights into optimizing rhythm control strategies in complex post-PCI patients. Learning Objectives Evaluate the safety profile and clinical outcomes associated with Class 1c antiarrhythmic therapy in patients with new-onset atrial fibrillation following PCI. Identify appropriate patient selection criteria and…

More episodes of The Lead Podcast presented by Heart Rhythm Society

Explore listener stats, chart rankings, contacts and more on the The Lead Podcast presented by Heart Rhythm Society podcast page.